Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05717127

Metabolic Impact of Intermittent Fasting in Early Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2, Obesity

Sex: All
Ages: 20 Years – 70 Years
Phase: NA
Enrollment: 50
Sponsor: Mount Sinai Hospital, Canada

Location: Canada

Summary

One known cause of type 2 diabetes (T2DM) is beta-cell dysfunction, which refers to the inability of the beta-cells of the pancreas to produce enough insulin for the body's needs. Unfortunately, no anti-diabetic medication or lifestyle intervention has been shown to prevent the worsening of beta-cell function over time. Interestingly, however, intermittent fasting (IF) - where no food is consumed over a period of time - has been shown to promote weight loss and improve cardio-metabolic function. In individuals with T2DM, it is also been shown to improve glycemic control (i.e. reduce the sugar levels). While no research has studied whether IF can improve pancreatic beta-cell function, the positive metabolic effects suggest that it could provide some benefit. The current study will evaluate whether IF can improve pancreatic beta-cell function in individuals with early T2DM.

Eligibility Criteria

Inclusion Criteria:Men and women with type 2 diabetes mellitus diagnosed within preceding 10 yearsAge 20-70 years inclusiveBody mass index ≥ 25 kg/m2Diabetes treatment consisting of lifestyle only, metformin or dipeptidyl peptidase-4 (DPP-4) inhibitor either as monotherapy or in combinationHbA1c value of 5.5 - 9.0% inclusiveExclusion Criteria:Current diabetes treatment with insulin, glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter 2 (SGLT-2) and/or sulfonylureasInvolvements in any other clinical study on lifestyle intervention or requiring drug therapyAny history or eating disorderRenal dysfunction as evidenced by estimated glomerular filtration rate <45 mL/min by Modification of Diet in Renal Disease (MDRD) formulaHepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases >2.5x the upper limit of normalMalignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)Any other factor likely to limit adherence to the study, in the opinion of the investigators

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05717127). StuddyBuddy aggregates publicly available trial information.